Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biden Administration, the most common co-covered peer. Part D appears in 1 tracked Cross-Sector story from July 30, 2026. The tracked stories average 5 original sources each.
1 verified story tracked
Last mentioned: Jul 30, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biden Administration, the most common co-covered peer. Part D appears in 1 tracked Cross-Sector story from July 30, 2026. The tracked stories average 5 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Part D. Shared-story counts are live from our verified record — not editorial picks.
Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.
Source: orlandosentinel.com · citizensvoice.com
